Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial

American Heart Journal

Volumn 145, Issue 2, 2003, Pages 239-247

  Gurbel, Paul A ^a,b   Cummings, Charles C ^a   Bell, Christopher R ^a   Alford, Amanda B ^a   Meister, Andrew F ^a   Serebruany, Victor L ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b Sinai Center for Thrombasis Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CELL ADHESION MOLECULE; CLOPIDOGREL; COLLAGEN; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; RECEPTOR; THROMBOCYTE SLOWING FACTOR;

ADULT; AGED; ARTICLE; BLOOD; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; ELECTIVE SURGERY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HEART CONTRACTION; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SUBSTITUTION THERAPY; SURFACE PROPERTY; THROMBOCYTE AGGREGATION;

EID: 0037326063     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.109     Document Type: Article

References (32)

1. Gurbel PA, O'Connor CM, Cummings CC, et al. Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Pharmacol Res 1999;40:107-11.
2. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y (AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19:2007-11.
3. Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-52.
4. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-9.
5. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery-stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
6. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
7. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34: 1891-4.
8. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99: 2364-6.
9. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101:590-3.
10. Bertrand ME, Rupprecht H-J, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102: 624-9.
11. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25(2 Suppl):15-9.
12. Thebault JJ, Kieffer G, Cariou R. Single dose pharmaco-dynamics of clopidogrel. Semin Thromb Hemost 1999;25(2 Suppl):3-8.
13. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823-8.
14. Gurbel PA, Serebruany VL, Shustov AR, et al. Global use of strategies to open occluded coronary arteries: effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. J Am Coll Cardiol 1998;31:1466-73.
15. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-39.
16. Elwood PC, Beswick AD, Sharp DS, et al. Whole blood impedence aggregometry and ischemic heort disease: the Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 1990;10:1032-6.
17. Gurbel PA, Kereiakes DJ, Dalesandro MR, et al. Role of soluble and platelet-bound P-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. Am Heart J 2000;139:320-8.
18. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
19. Carr ME. Measurement of platelet force: the Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995;9:312-4,316-8,320.
20. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patents. Thromb Haemost 1996;76:939-43.
21. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104-11.
22. Carr ME Jr, Carr SL, Hantgan RR, et al. Glycoprotein IIb/IIIa blockade inhibits platelet mediated force development and reduces gell elastic modulus. Thromb Haemost 1995;73:499-505.
23. Bennett JS, Chan C, Vilaire G, et al. Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Biol Chem 1997;272:8137-40.
24. Gawaz M, Neumann FJ, Schomig A. Evaluation of membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999;99:E1-11.
25. Yuan Y, Dopheide SM, Ivanidis C, et al. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets: distinct roles of glycoprotein Ib-V-IX and glycoprotein IIb/IIIa (integrin alpha11bbeta3) in von Willebrand factor-induced signal transduction. J Biol Chem 1997;272:21847-54.
26. Serebruany VL, Gurbel PA. Effects of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:153-8.
27. Newman PJ, Berndt MC, Gorsky J, et al. PECAM-1 (CD 31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990;247:1219-22.
28. Varon D, Jackson DE, Shenkman B, et al. Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets. Blood 1998;91:500-7.
29. Sincock PM, Mayrhofer G, Ashman LK. Localization of transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD 9, CD 63 and alpha5beta1 integrin. J Histochem and Cytochem 1997;45:515-25.
30. Roberts JJ, Rodgers SE, Drury J, et al. Platelet activation induced by a murine monoclonal antibody directed against a novel tetraspan antigen. Br J Haematol 1995;89:853-60.
31. Sueyoshi S, Sawada R, Fukuda M. Carbohydrate structures of recombinant soluble lamp-1 and leukosialin containing sialyl Le (x) terminus. Bioorg Med Chem 1994;2:1331-8.
32. Gurbel PA, Serebruany VL. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. J Thrombosis Thrombolysis 2000;10:217-20.